HIGHTIDE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.48 HKD | +0.45% |
|
-12.33% | -65.43% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 6,064 | 2,139 | - | - |
| Enterprise Value (EV) 1 | 5,472 | 2,167 | 2,540 | 3,511 |
| P/E ratio | -3.25 x | -7.34 x | -6.46 x | -8.28 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 713,104 x |
| EV / Revenue | - | - | - | 1,170,458 x |
| EV / EBITDA | - | -7.67 x | -8.19 x | -17.8 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | -23.3 x | -5.06 x | -3.14 x |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | - | - |
| Reference price 2 | 11.78 | 4.156 | 4.156 | 4.156 |
| Announcement Date | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales | - | - | - | 3,000 |
| EBITDA 1 | - | -282.7 | -310.3 | -197.4 |
| EBIT 1 | -448.2 | -284.2 | -312.7 | -210 |
| Operating Margin | - | - | - | -7% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -3.620 | -0.5663 | -0.6430 | -0.5018 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | 28 | 400 | 1,372 |
| Net Cash position 1 | 592 | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.0991 x | -1.291 x | -6.952 x |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share 2 | - | -0.1800 | -0.8200 | -1.320 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 5.8 | 50.8 | 451 |
| Capex / Sales | - | - | - | 15.03% |
| Announcement Date | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.156
CNY
Average target price
15.62
CNY
Spread / Average Target
+275.86%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -65.43% | 294M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.57B | |
| +3.23% | 22.82B | |
| -10.44% | 18.19B | |
| -41.74% | 16.54B | |
| -13.31% | 16.5B | |
| +2.44% | 13.39B | |
| +27.89% | 11.1B |
- Stock Market
- Equities
- 2511 Stock
- Financials HighTide Therapeutics, Inc.
